Abstract Background Idiopathic Pulmonary Fibrosis (IPF) or Usual Interstitial Pneumonia
(UIP) is a form of chronic fibrosing interstitial pneumonia of unknown aetiology, with …

Background Idiopathic Pulmonary Fibrosis (IPF) or Usual Interstitial Pneumonia (UIP) is a
form of chronic fibrosing interstitial pneumonia of unknown aetiology, with progressively …

Background Idiopathic pulmonary fibrosis (IPF) is a disease with significant morbidity and
mortality. Patients short survival time, high mortality and generally rapid decline raise the …

Idiopathic pulmonary fibrosis (IPF) is a lethal form of idiopathic diffuse lung disorders for
which no current treatment is effective. The aim of the present study was to systematically …

Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death
within a few years of diagnosis despite medical therapy. On the basis of methodologies of …

Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to
treat IPF. On the other hand, the placebo arms of these large trials have provided us with …

Corticosteroids were the mainstay of therapy for idiopathic pulmonary fibrosis (IPF) for more
than four decades, but their efficacy is unproven and toxicities are substantial. The course of …

Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease with a median survival
of 2–4 years after diagnosis. Since the publication of the German IPF guideline in 2013 new …

Background Most data on outcomes in Idiopathic Pulmonary Fibrosis (IPF) pre-dates current
guidelines. Data on rates of infection is sparse; the effect of low-dose corticosteroids and …